Skip to main content
SpringerLink
Log in

Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The kinetics of moxalactam has been investigated in 10 subjects undergoing continuous ambulatory peritoneal dialysis (CAPD). A single 1 g dose was injected i.v. and a 1 g dose was given intraperitoneally in the CAPD fluid during a 4 h dwell-time. Moxalactam was assayed by HPLC. After i.v. injection, the serum kinetics of moxalactam were: plasma t 1/2=17.9 h; volume of distribution at steady-state, 0.27 l/kg; total plasma clearance, 12.8 ml/min; peritoneal clearance, 2.1 ml/min. Dialysate moxalactam concentrations rose rapidly but only 20% of the dose was eliminated by the peritoneal route. After intraperitoneal instillation, moxalactam appeared in the serum rapidly and the peak serum concentration ranged from 21 to 49 µg/ml after between 4 and 5 h. The absorption of moxalactam from the peritoneal space was 57±16%. The data suggest that moxalactam has bidirectional exchange characteristics through the peritoneal membrane. Instillation of moxalactam in CAPD fluid may permit rapid absorption and the appearance of a therapeutic serum concentration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C (1985) Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 38: 285–289

    Google Scholar 

  2. Bolton WK, Scheld WM, Spyker DA, Overby TL, Sande MA (1980) Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction. Antimicrob Agents Chemother 18: 933–938

    Google Scholar 

  3. Bunke CM, Aronoff GR, Brier HE, Sloan RS, Luft FC (1983) Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 33: 66–72

    Google Scholar 

  4. Carmine AA, Brogden RN, Heel RC, Romankiewicz JA, Speight TM, Avery GS (1983) Moxalactam (latamoxef): a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 26: 279–333

    Google Scholar 

  5. Diven WF, Obermeyer BD, Wolen RL, Yu VL, Lyon J, Zurayleff J (1981) Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography. Ther Drug Monit 3: 291–295

    Google Scholar 

  6. Gibson TP, Matusals E, Nelson LD, Briggs WA (1976) Artifical kidneys and clearance calculations. Clin Pharmacol Ther 20: 720–726

    Google Scholar 

  7. Gomeni R (1984) Pharm-An interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 14 [1] 25–34

    Google Scholar 

  8. Gross ML, Somani P, Ribner BS, Raeder R, Freimer EH, Higgins JT (1983) Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34: 673–680

    Google Scholar 

  9. Hodler JE, Galeazzi RL, Frey B, Rudhardt, Seiler AJ (1984) Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: Eur J Clin Pharmacol 26: 609–612

    Google Scholar 

  10. Jacobson EJ, Zahrowski JJ, Nissenson AR (1981) Moxalactam kinetics in hemodialysis. Clin Pharmacol Ther 30: 487–490

    Google Scholar 

  11. Lam M, Manion CV, Czerwinski AW (1981) Pharmacokinetics of moxalactam in patients with renal insufficiency. Antimicrob Agents Chemother 19: 461–464

    Google Scholar 

  12. Leroy A, Humbert G, Fillastre JP (1981) Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother 19: 965–971

    Google Scholar 

  13. Paton WT, Cornish WR, Manuel MA, Hardy BG (1985) Drug therapy in patients undergoing peritoneal dialysis: clinical pharmacokinetics considerations. Clin Pharmacokiner 10: 404–426

    Google Scholar 

  14. Petersen J, Stewart RDM, Catto GRD, Edward N (1985) Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis. Nephron 40: 79–82

    Google Scholar 

  15. Singlas E, Boutron HF, Merdjan H, Brocard JF, Pocheville M, Fries D (1983) Moxalactam kinetics during chronic ambulatory peritoneal dialysis. Clin Pharmacol Ther 34: 403–407

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Hôpital Pellgrin, Bordeaux, France

    H. Albin, F. Demotes-Mainard & G. Vincon

  2. Department of Nephrology, Hôpital Saint André, Bordeaux, France

    J. M. Ragnaud & C. Wone

  3. Centre de Pharmacologie Clinique, Université de Bordeaux II, Rue Léo Saignat, F-33076, Bordeaux, France

    H. Albin

Authors
  1. H. Albin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Ragnaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Demotes-Mainard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Vincon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Wone
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Albin, H., Ragnaud, J.M., Demotes-Mainard, F. et al. Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis. Eur J Clin Pharmacol 30, 299–302 (1986). https://doi.org/10.1007/BF00541532

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00541532

Key words

Search

Navigation